Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amphotericin b
Drug ID BADD_D00132
Description Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Indications and Usage Used to treat potentially life threatening fungal infections.
Marketing Status Prescription; Discontinued
ATC Code A01AB04; A07AA07; G01AA03; J02AA01
DrugBank ID DB00681
KEGG ID D00203
MeSH ID D000666
PubChem ID 14956
TTD Drug ID D02DWM
NDC Product Code 38779-0191; 63622-0125; 63622-0123; 65044-7183; 51552-0304; 51927-1726; 45932-0008; 55500-0001; 63622-0124; 62991-1173; 62756-233; 39822-1055; 0469-3051
Synonyms Amphotericin B | Amphotericin | Fungizone | Amphotericin B Cholesterol Dispersion | Amphotericin B Colloidal Dispersion | Amphocil
Chemical Information
Molecular Formula C47H73NO17
CAS Registry Number 1397-89-3
SMILES CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O) O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Folliculitis11.01.12.018; 23.09.04.007--
Fungaemia11.01.11.0020.000108%
Fungal infection11.03.05.0010.000323%Not Available
Gamma-glutamyltransferase increased13.03.01.0110.000618%
Gastroenteritis07.19.03.001; 11.01.07.004--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema08.01.07.004; 14.05.06.007--
Gingival bleeding07.09.07.001; 24.07.02.010--Not Available
Gingivitis07.09.03.003; 11.01.04.013--
Glossitis07.14.01.001--Not Available
Glycosuria20.02.01.005--
Graft versus host disease10.02.01.027; 12.02.09.001--Not Available
Haematemesis07.12.02.002; 24.07.02.011--Not Available
Haematuria20.02.01.006; 24.07.01.047--
Haemoglobin13.01.05.018--Not Available
Haemoptysis02.01.02.006; 22.02.03.004; 24.07.01.006--Not Available
Haemorrhoids07.15.03.001; 24.10.02.002--
Hallucination19.10.02.002--
Headache17.14.01.001--
Heart rate increased13.14.04.0020.000618%Not Available
Hepatic failure09.01.03.0020.000215%
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.0040.000215%Not Available
Hepatitis cholestatic09.01.01.0020.000412%Not Available
Hepatocellular injury09.01.07.008--Not Available
Hepatomegaly09.01.05.001--Not Available
Hepatotoxicity09.01.07.009; 12.03.01.0080.000412%Not Available
Herpes simplex11.05.02.001; 23.09.03.001--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene